Caribou Biosciences, Inc. / Fundamentals
Income statement
- Net revenue
€7.86M - Cost of goods sold
€0.00 - Gross profit
€6.84M - SG&A expenses
€34.86M - R&D expenses
€106.93M - EBITDA
-€130.90M - D&A
€3.03M - EBIT
-€144.40M - Interest expenses
€0.00 - EBT
-€141.53M - Tax expenses
-€7.75K - Net income
-€141.52M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€15.56M - Changes in working capital
-€4.15M - Operating cash flow
-€114.68M - Capex
€2.28M - Other investing cash flow
€2.84M - Net investing cash flow
€99.83M - Total cash dividends paid
€0.00 - Issuance of common stock
€3.15M - Debt repayment
€0.00 - Other financing cash flow
€791.76K - Net financing cash flow
€3.95M - Foreign exchange effects
€0.00 - Net change in cash
-€10.87M - Cash at end of period
€21.75M - Free cash flow
-€112.40M
Balance sheet
- Cash and cash equivalents
€21.71M - Cash and short-term investments
€158.48M - Total receivables
€2.40M - Inventory
€0.00 - Other current assets
€4.98M - Total current assets
€165.85M - Property, plant & equipment
€21.23M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€153.36K - Other non-current assets
€3.08M - Total non-current assets
€24.47M - Total assets
€190.32M - Accounts payable
€2.79M - Short-term debt
€1.97M - Other current liabilities
€17.69M - Total current liabilities
€24.89M - Long-term debt
€40.60M - Deferred tax liabilities
€472.13K - Other non-current liabilities
€0.00 - Total non-current liabilities
€22.30M - Total liabilities
€47.19M - Common stock
€7.75K - Retained earnings
-€467.37M - Other equity
€34.46K - Total equity
€143.13M - Total liabilities and shareholders' equity
€190.32M
Company information
- Market capitalization
€99.95M - Employees
147 - Enterprise Value
€106.55M
Company ratios
- Gross margin
-
87.0% Much better than peer group: -5,021,660,012,663,959,000.0% - EBITDA margin
-
-1,665.8% Much better than peer group: -7,684,097,560,812,432,000.0% - EBIT margin
-
-1,837.6% Much better than peer group: -7,392,174,625,121,632,000.0% - EBT margin
-
-1,801.0% Much better than peer group: -8,738,449,596,452,130,000.0% - Net margin
-
-1,800.9% Much better than peer group: -8,738,449,596,452,130,000.0% - ROE
-
-98.9% Much worse than peer group: -32.5% - ROA
-
-74.4% Much worse than peer group: -35.9% - Asset turnover
-
4.1% Even with peer group: 6.9% - FCF margin
-
-1,488.5% Much better than peer group: -6,531,462,015,305,486,000.0% - FCF yield
-117.0% - Efficiency ratio
1,765.8% - Net sales per employee
-
€53.46K - Net income per employee
-
-€962.73K